Prelude Historical Financial Ratios

PRLD Stock

USD 0.76 0.08 11.68%

Prelude Therapeutics is promptly reporting on over 82 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 2.1, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 2.44 will help investors to properly organize and evaluate Prelude Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

About Prelude Financial Ratios Analysis

Prelude TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Prelude Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Prelude financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Prelude Therapeutics history.

Prelude Therapeutics Financial Ratios Chart

At present, Prelude Therapeutics' Book Value Per Share is projected to slightly grow based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.77, whereas Operating Cash Flow Per Share is forecasted to decline to (1.43).

Price To Sales Ratio Ev To Sales Payables Turnover Capex To Revenue

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Prelude Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Prelude Therapeutics sales, a figure that is much harder to manipulate than other Prelude Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most ratios from Prelude Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Prelude Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.At present, Prelude Therapeutics' Book Value Per Share is projected to slightly grow based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.77, whereas Operating Cash Flow Per Share is forecasted to decline to (1.43).

	2024	2025 (projected)
Interest Debt Per Share	0.24	0.25
Revenue Per Share	0.0831	0.0738

Interest Debt Per Share Revenue Per Share

Prelude Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Net Debt To E B I T D A
Price To Sales Ratio		-0.39	-0.16	0.87	0.36	0.74	-0.39	1.0	0.34	0.0	0.35	-0.13	1.0	-0.09	-0.53	-0.75	-0.53	0.27	-0.11	0.64	-0.53	-0.53	-0.03	-0.53	0.88	0.39
Ptb Ratio	-0.39		0.89	-0.58	-0.91	-0.82	1.0	-0.39	-0.9	0.71	-0.9	0.7	-0.39	0.88	0.76	0.81	0.75	-0.84	-0.58	-0.91	0.78	0.79	0.75	0.77	-0.58	-0.04
Book Value Per Share	-0.16	0.89		-0.36	-0.88	-0.53	0.89	-0.16	-0.88	0.93	-0.9	0.71	-0.16	0.99	0.65	0.55	0.64	-0.76	-0.77	-0.8	0.67	0.68	0.94	0.66	-0.36	-0.01
Free Cash Flow Yield	0.87	-0.58	-0.36		0.62	0.79	-0.58	0.88	0.61	-0.2	0.61	-0.42	0.88	-0.28	-0.78	-0.79	-0.78	0.56	0.16	0.84	-0.78	-0.78	-0.24	-0.78	1.0	0.55
Operating Cash Flow Per Share	0.36	-0.91	-0.88	0.62		0.65	-0.91	0.36	1.0	-0.69	1.0	-0.87	0.36	-0.86	-0.92	-0.61	-0.92	0.95	0.63	0.91	-0.93	-0.94	-0.72	-0.93	0.61	0.39
Capex To Depreciation	0.74	-0.82	-0.53	0.79	0.65		-0.82	0.74	0.63	-0.32	0.64	-0.44	0.74	-0.5	-0.66	-0.97	-0.65	0.62	0.29	0.84	-0.67	-0.68	-0.37	-0.67	0.8	0.08
Pb Ratio	-0.39	1.0	0.89	-0.58	-0.91	-0.82		-0.39	-0.9	0.71	-0.9	0.7	-0.39	0.88	0.76	0.81	0.75	-0.84	-0.58	-0.91	0.78	0.79	0.75	0.77	-0.58	-0.04
Ev To Sales	1.0	-0.39	-0.16	0.88	0.36	0.74	-0.39		0.34	0.0	0.35	-0.13	1.0	-0.09	-0.53	-0.75	-0.53	0.27	-0.11	0.64	-0.53	-0.53	-0.03	-0.53	0.88	0.39
Free Cash Flow Per Share	0.34	-0.9	-0.88	0.61	1.0	0.63	-0.9	0.34		-0.69	1.0	-0.88	0.34	-0.87	-0.92	-0.6	-0.92	0.95	0.64	0.9	-0.93	-0.94	-0.72	-0.92	0.6	0.39
Roic	0.0	0.71	0.93	-0.2	-0.69	-0.32	0.71	0.0	-0.69		-0.71	0.51	0.0	0.89	0.39	0.38	0.38	-0.5	-0.75	-0.64	0.41	0.43	1.0	0.4	-0.2	0.19
Net Income Per Share	0.35	-0.9	-0.9	0.61	1.0	0.64	-0.9	0.35	1.0	-0.71		-0.88	0.36	-0.88	-0.91	-0.61	-0.91	0.95	0.69	0.91	-0.92	-0.93	-0.74	-0.92	0.6	0.38
Payables Turnover	-0.13	0.7	0.71	-0.42	-0.87	-0.44	0.7	-0.13	-0.88	0.51	-0.88		-0.13	0.7	0.83	0.31	0.83	-0.93	-0.74	-0.71	0.83	0.83	0.53	0.83	-0.42	-0.46
Capex To Revenue	1.0	-0.39	-0.16	0.88	0.36	0.74	-0.39	1.0	0.34	0.0	0.36	-0.13		-0.09	-0.54	-0.75	-0.54	0.27	-0.1	0.64	-0.53	-0.54	-0.03	-0.53	0.89	0.39
Cash Per Share	-0.09	0.88	0.99	-0.28	-0.86	-0.5	0.88	-0.09	-0.87	0.89	-0.88	0.7	-0.09		0.62	0.51	0.61	-0.76	-0.75	-0.74	0.64	0.65	0.91	0.63	-0.27	0.03
Pocfratio	-0.53	0.76	0.65	-0.78	-0.92	-0.66	0.76	-0.53	-0.92	0.39	-0.91	0.83	-0.54	0.62		0.61	1.0	-0.93	-0.44	-0.88	1.0	1.0	0.42	1.0	-0.77	-0.68
Capex To Operating Cash Flow	-0.75	0.81	0.55	-0.79	-0.61	-0.97	0.81	-0.75	-0.6	0.38	-0.61	0.31	-0.75	0.51	0.61		0.6	-0.54	-0.25	-0.83	0.62	0.63	0.43	0.61	-0.79	-0.03
Pfcf Ratio	-0.53	0.75	0.64	-0.78	-0.92	-0.65	0.75	-0.53	-0.92	0.38	-0.91	0.83	-0.54	0.61	1.0	0.6		-0.92	-0.44	-0.87	1.0	1.0	0.42	1.0	-0.77	-0.69
Days Payables Outstanding	0.27	-0.84	-0.76	0.56	0.95	0.62	-0.84	0.27	0.95	-0.5	0.95	-0.93	0.27	-0.76	-0.93	-0.54	-0.92		0.62	0.82	-0.93	-0.94	-0.54	-0.93	0.55	0.46
Income Quality	-0.11	-0.58	-0.77	0.16	0.63	0.29	-0.58	-0.11	0.64	-0.75	0.69	-0.74	-0.1	-0.75	-0.44	-0.25	-0.44	0.62		0.54	-0.46	-0.47	-0.75	-0.45	0.17	0.03
Roe	0.64	-0.91	-0.8	0.84	0.91	0.84	-0.91	0.64	0.9	-0.64	0.91	-0.71	0.64	-0.74	-0.88	-0.83	-0.87	0.82	0.54		-0.89	-0.9	-0.67	-0.88	0.84	0.33
Ev To Operating Cash Flow	-0.53	0.78	0.67	-0.78	-0.93	-0.67	0.78	-0.53	-0.93	0.41	-0.92	0.83	-0.53	0.64	1.0	0.62	1.0	-0.93	-0.46	-0.89		1.0	0.44	1.0	-0.77	-0.66
Pe Ratio	-0.53	0.79	0.68	-0.78	-0.94	-0.68	0.79	-0.53	-0.94	0.43	-0.93	0.83	-0.54	0.65	1.0	0.63	1.0	-0.94	-0.47	-0.9	1.0		0.46	1.0	-0.78	-0.64
Return On Tangible Assets	-0.03	0.75	0.94	-0.24	-0.72	-0.37	0.75	-0.03	-0.72	1.0	-0.74	0.53	-0.03	0.91	0.42	0.43	0.42	-0.54	-0.75	-0.67	0.44	0.46		0.44	-0.23	0.19
Ev To Free Cash Flow	-0.53	0.77	0.66	-0.78	-0.93	-0.67	0.77	-0.53	-0.92	0.4	-0.92	0.83	-0.53	0.63	1.0	0.61	1.0	-0.93	-0.45	-0.88	1.0	1.0	0.44		-0.77	-0.67
Earnings Yield	0.88	-0.58	-0.36	1.0	0.61	0.8	-0.58	0.88	0.6	-0.2	0.6	-0.42	0.89	-0.27	-0.77	-0.79	-0.77	0.55	0.17	0.84	-0.77	-0.78	-0.23	-0.77		0.54
Net Debt To E B I T D A	0.39	-0.04	-0.01	0.55	0.39	0.08	-0.04	0.39	0.39	0.19	0.38	-0.46	0.39	0.03	-0.68	-0.03	-0.69	0.46	0.03	0.33	-0.66	-0.64	0.19	-0.67	0.54

Click cells to compare fundamentals

Prelude Therapeutics Account Relationship Matchups

Prelude Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	14.74	2.07	1.46	1.09	0.73	0.77
Book Value Per Share	4.85	6.01	4.13	3.93	1.73	2.1
Free Cash Flow Yield	(0.015)	(0.14)	(0.3)	(0.43)	(1.08)	(1.02)
Operating Cash Flow Per Share	(0.79)	(1.06)	(1.75)	(1.77)	(1.36)	(1.43)
Capex To Depreciation	1.15	2.54	2.28	3.01	0.43	0.41
Pb Ratio	14.74	2.07	1.46	1.09	0.73	0.77
Free Cash Flow Per Share	(0.82)	(1.07)	(1.8)	(1.83)	(1.37)	(1.44)
Roic	(0.28)	(0.39)	(0.57)	(0.51)	(0.92)	(0.96)
Net Income Per Share	(1.3)	(2.33)	(2.27)	(2.02)	(1.68)	(1.76)
Payables Turnover	0.19	0.14	0.29	0.45	0.26	0.23
Cash Per Share	4.99	6.12	4.26	3.86	1.76	2.52
Pocfratio	(67.72)	(7.09)	(3.42)	(2.41)	(0.94)	(0.98)
Capex To Operating Cash Flow	(0.0134)	(0.0278)	(0.0361)	(0.0328)	(0.007426)	(0.007797)
Pfcf Ratio	(66.82)	(6.9)	(3.3)	(2.33)	(0.93)	(0.98)
Days Payables Outstanding	2.6K	1.3K	813.15	1.4K	1.6K	2.1K
Roe	(0.27)	(0.39)	(0.55)	(0.51)	(0.97)	(0.92)
Ev To Operating Cash Flow	(62.99)	(6.73)	(3.07)	(2.33)	(0.99)	(1.04)
Pe Ratio	(54.93)	(5.35)	(2.67)	(2.12)	(0.76)	(0.79)
Return On Tangible Assets	(0.25)	(0.36)	(0.49)	(0.44)	(0.72)	(0.76)
Ev To Free Cash Flow	(62.16)	(6.55)	(2.97)	(2.25)	(0.98)	(1.03)
Earnings Yield	(0.0182)	(0.19)	(0.38)	(0.47)	(1.32)	(1.25)
Net Debt To E B I T D A	3.75	0.27	0.24	0.0641	(0.0397)	(0.0377)
Current Ratio	19.41	15.37	9.42	10.79	5.3	8.1
Tangible Book Value Per Share	4.85	6.01	4.13	3.93	1.73	2.1
Shareholders Equity Per Share	4.85	6.01	4.13	3.93	1.73	2.1
Capex Per Share	0.0142	0.0488	0.0637	0.0582	0.0101	0.009574
Graham Net Net	4.73	5.71	3.73	3.19	1.18	1.85
Enterprise Value Over E B I T D A	(49.96)	(4.99)	(2.11)	(1.9)	(0.73)	(0.77)
Price Earnings Ratio	(54.93)	(5.35)	(2.67)	(2.12)	(0.76)	(0.79)
Price Book Value Ratio	14.74	2.07	1.46	1.09	0.73	0.77
Price Earnings To Growth Ratio	(1.04)	(0.0675)	1.04	0.19	0.045	0.0472
Days Of Payables Outstanding	2.6K	1.3K	813.15	1.4K	1.6K	2.1K
Price To Operating Cash Flows Ratio	(67.72)	(7.09)	(3.42)	(2.41)	(0.94)	(0.98)
Price To Free Cash Flows Ratio	(66.82)	(6.9)	(3.3)	(2.33)	(0.93)	(0.98)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:

How To Invest In Prelude

Details

Is Prelude Stock a good investment?

Details

What is Prelude Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.79)

Revenue Per Share

0.092

Return On Assets

(0.39)

Return On Equity

(0.69)

The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Prelude Historical Financial Ratios

About Prelude Financial Ratios Analysis

Prelude Therapeutics Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Payables Turnover

Capex To Revenue

Prelude Therapeutics fundamentals Correlations

Prelude Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Prelude Therapeutics fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Capex To Revenue	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Earnings Yield	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Operating Cash Flow Per Share

Capex To Operating Cash Flow	- 0.97	Capex To Depreciation
Pe Ratio	- 0.94	Days Payables Outstanding
Pe Ratio	- 0.94	Free Cash Flow Per Share
Pe Ratio	- 0.94	Operating Cash Flow Per Share
Ev To Free Cash Flow	- 0.93	Days Payables Outstanding
Ev To Operating Cash Flow	- 0.93	Days Payables Outstanding